secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexeo Therapeutics, Inc. (LXEO)
CIK:        0001907108
Form:       8-K
Filed at:   2026-08-12T11:02:57+00:00
Accession:  0001193125-26-345722
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexeo Q2 net loss $25.9M; initiates LX2006 pivotal trial, gains RMAT for LX2020
-------------------------------------------------------------------------------

- Net loss $25.9M ($0.30/sh) vs $26.1M ($0.60/sh) YoY; R&D $19.0M vs $14.7M, G&A $9.0M vs $16.0M.
- Cash, equivalents and investments $234.2M expected to fund operations into 2028.
- First patient enrolled in SUNRISE-FA 2 pivotal trial for LX2006 in FA cardiomyopathy; topline data expected 2H 2027.
- FDA granted RMAT designation for LX2020 in PKP2-ACM; 12-month high-dose data update expected Q4 2026.
- LX2006 data published in JAMA Cardiology showing generally well tolerated with signs of efficacy in Phase I/II.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1907108/000119312526345722/0001193125-26-345722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1907108/000119312526345722/lxeo-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-345722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer